This is a positive clinical execution milestone that de-risks the U.S. regulatory pathway for ateganosine, but no new efficacy data was released. Monitor for interim THIO-101 data readouts and any FDA accelerated approval filing updates. The $2.3M NIH grant extends cash runway modestly for a sub-$100M market cap company.
Price Chart
Executive Summary
MAIA Biotechnology dosed the first U.S. patient in the Phase 2 THIO-101 trial expansion for ateganosine in third-line NSCLC, funded by a $2.3M NIH grant. The milestone follows FDA clearance of an amended IND and activates 3 U.S. sites, with prior data showing OS beyond 24 months in eight patients. This is a clinical execution milestone for a pre-revenue biotech, advancing a potential accelerated approval pathway but with no new efficacy or safety data released.
Key Financial Metrics
Key Facts
- First U.S. patient dosed in Phase 2 THIO-101 expansion for ateganosine in third-line NSCLC
- Funded by a $2.3 million NIH grant
- 3 U.S. sites activated; patients enrolled across four continents
- Prior data from THIO-101 Parts A and B showed OS beyond 24 months in eight patients
- Ateganosine holds FDA Fast Track designation
- FDA cleared amended IND for improved manufacturing capabilities
Financial Impact
Clinical milestone for pre-revenue biotech; $2.3M NIH grant funds U.S. expansion; no revenue impact yet
Risk Factors
- No new efficacy or safety data released; prior OS data is from a small subset (8 patients)
- Clinical-stage biotech with no approved products; high binary risk on future trial results
- Dilution risk remains for ongoing operations beyond NIH grant funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3363142 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | EFFECT | $1.18 | awaiting T+60 | — | $1.11 (+5.93%) |
Oct 6, 2026 20d ago | 8-K | $1.19 | awaiting T+60 | — | $1.11 (−6.72%) |
Sep 25, 2026 4w ago | S-3 | $1.18 | awaiting T+60 | — | $1.11 (+5.93%) |
Sep 16, 2026 5w ago | Press Release | $1.40 | awaiting T+60 | — | $1.11 (−20.71%) |
Sep 15, 2026 5w ago | Press Release | $1.34 | awaiting T+60 | — | $1.11 (−17.16%) |
Sep 15, 2026 5w ago | Insider Cluster | $1.34 | awaiting T+60 | — | $1.11 (−17.16%) |
Jun 3, 2026 20w ago | Press Release | $1.43 $1.38 | ▼ −3.50% | ▼ −6.00% | $1.11 (−22.38%) |
Jun 2, 2026 20w ago | Insider Cluster | $1.35 $1.39 | ▲ +2.96% | ▲ +1.85% | $1.11 (−17.78%) |
May 19, 2026 22w ago | DEFA14A | $1.23 $1.34 | ▲ +8.94% | ▲ +2.65% | $1.11 (−9.76%) |
May 14, 2026 23w ago | 8-K | $1.26 $1.38 | ▲ +9.52% | ▲ +5.01% | $1.11 (−11.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers